Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.48 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.48 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.48 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.48 |
| ▸ | CBFB | Q13951 | 1/20 | 0.48 |
| ▸ | TERT | O14746 | 7/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.35 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3727450 | 1.00 | MEN1 (0.48) | MEN1NPC1RAB9AKMT2AKDM4E | |
| SCHEMBL21345205 | 0.94 | MAPT (0.43) | MEN1NPC1RAB9AKMT2AKDM4E | |
| SCHEMBL10092627 | 0.82 | CYP17A1 (0.48) | MAP4K4NR1H4CYP17A1MAPKAPK2PSMB8 | |
| SCHEMBL14155353 | 0.82 | CYP17A1 (0.48) | MAP4K4NR1H4CYP17A1MAPKAPK2PSMB8 | |
| SCHEMBL5383433 | 0.82 | MEN1 (0.61) | MEN1NPC1RAB9AKMT2AKDM4E | |
| SCHEMBL3778070 | 0.81 | POLB (0.43) | MEN1NPC1RAB9AKMT2AKDM4E | |
| SCHEMBL3778074 | 0.81 | POLB (0.43) | MEN1NPC1RAB9AKMT2AKDM4E | |
| SCHEMBL13785800 | 0.81 | POLB (0.43) | MEN1NPC1RAB9AKMT2AKDM4E | |
| SCHEMBL21017931 | 0.81 | KDM4E (0.44) | NPC1RAB9AKDM4EMAPTGLA | |
| SCHEMBL13293398 | 0.80 | CYP17A1 (0.43) | MAP4K4NR1H4CYP17A1GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825279-B2 | Fused ring dicationic anti-protozoan agents and their prodrugs | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2010-11-02 | — | — | US | disclosed |
| US-20050165044-A1 | Fused ring dicationic anti-protozoan agents and their prodrugs | BOYKIN DAVID W (US) | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165044-A1 | Fused ring dicationic anti-protozoan agents and their prodrugs | DHODH, DHFR, PAICS | MEN1 1639/4885NPC1 1942/4885RAB9A 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.